Everything below concerns immunomodulator. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
=== Clonidine suppression test === The reduction in circulating norepinephrine by clonidine was used in the past as an investigatory test for phaeochromocytoma, which is a catecholamine-synthesizing tumor, usually found in the adrenal medulla. In a clonidine suppression test, plasma catecholamine levels are measured before and 3 hours after a 0.3 mg oral test dose has been given to the patient. A positive test occurs if there is no decrease in plasma levels.
Until late 1976, black Rhodesians could not hold ranks higher than Sub-Inspector in the BSAP, only white Rhodesians could gain commissioned rank. After moderate black leader Bishop Abel Muzorewa was elected in the 1979 elections the promotion of African members hastened. After Robert Mugabe took power, the force followed a racial policy of "Africanisation", in which senior white officers were forcibly retired and their positions filled by black officers. The rank structure was unique; black policemen (known colloquially as "Mapolisa") were Constables, Sergeants, Senior Sergeants, Sergeant Majors, and Sub Inspectors. The white police (known colloquially as 'Majoni') ranks began at Patrol Officer (single gold bar on each shoulder), proceeding to Senior Patrol Officer (two gold bars), Section Officer (three gold bars), and thereafter to Inspector, Chief Inspector and commissioned ranks, etc., as per UK police rank structures. From 1977 Inspector and Chief Inspector became commissioned ranks to better align the Police ranks with those of the rest of the Security Forces. Lance and Staff rank prefixes were also used were appropriate in a similar manner to most Commonwealth armed forces. Members serving under CID had the prefix 'Detective' to their rank e.g. Detective Section Officer, abbreviated to D/SO. The prefix was dropped once a member attained the rank of Superintendent. White officers were assigned separate mess facilities to the black police and were obliged to employ black 'batmen'.
=== Dextran-crosslinked microspheres === One application of the glucose polymer dextran in microsphere compositions is as a cross-linker. Dextran and oxidized dextran can be used to crosslink gelatin microspheres to reduce gelatin dissolution, which slows the drug release rate. These dextran/gelatin microspheres can be used to provide slow-release of TRAPP-Br, which is a cancer therapeutic. Hydrogel microspheres synthesized by using porous chitosan polyelectrolyte complex with dextran sulfate as a cross-linker can deliver hydrophobic drugs to the intestines with high efficacy.
Following the re-election of Donald Trump in November 2024, Lula congratuled Trump on X (formerly Twitter) and again, after his inauguration, in January 2025, when Lula also highlighted Brazil-United States historical friendship. After Trump first threatened to impose tariffs on steel and aluminium in February 2025, and fulfilled that in March, Lula warned the United States economy could self-inflict damage, and promised to open a complaint against the 25% tariffs imposed on Brazilian steel and aluminum exports bound to US at the World Trade Organization. He also said he would not hesitate to call Trump to disscuss such tariffs, and hoped he answered his call.
Sources: en.wikipedia.org
Romé de l'Isle's Essai de cristallographie published in 1772 and Cristallographie published in 1783 the scientific approach to crystal structure began. Romé de l'Isle described over 500 crystal forms and accurately measured the interfacial angles of a great variety of crystals, using the goniometer designed by his student Arnould Carangeot. Romé de l'Isle noted that the angles are characteristic of a substance, thus generalizing the law of constancy of angles postulated by Steno. Romé de l'Isle considered that the shape of a crystal is a consequence of the packing of elemental particles, and defined six primitive forms. In 1781 René Just Haüy (often termed the "Father of Modern Crystallography") discovered that crystals always cleave along crystallographic planes. Based on this observation, and the fact that the inter-facial angles in each crystal species always have the same value, Haüy concluded that crystals must be periodic and composed of regularly arranged layers of tiny polyhedra (molécules intégrantes). This theory explained why all crystal planes are related by small rational numbers (the law of rational indices). In 1784 René-Just Haüy published Essai d'une théorie sur la structure des cristaux, appliquée à plusieurs genres de substances cristallisées in which he stated his law of decrements: a crystal is composed of molecules arranged periodically in three dimensions without leaving any gaps. Haüy's molecular crystal structure theory assumed that molécules intégrantes were specific in shape and composition for every compound.
At the ends of the linear chromosomes are specialized regions of DNA called telomeres. The main function of these regions is to allow the cell to replicate chromosome ends using the enzyme telomerase, as the enzymes that normally replicate DNA cannot copy the extreme 3′ ends of chromosomes. These specialized chromosome caps also help protect the DNA ends, and stop the DNA repair systems in the cell from treating them as damage to be corrected. In human cells, telomeres are usually lengths of single-stranded DNA containing several thousand repeats of a simple TTAGGG sequence. These guanine-rich sequences may stabilize chromosome ends by forming structures of stacked sets of four-base units, rather than the usual base pairs found in other DNA molecules. Here, four guanine bases, known as a guanine tetrad, form a flat plate. These flat four-base units then stack on top of each other to form a stable G-quadruplex structure. These structures are stabilized by hydrogen bonding between the edges of the bases and chelation of a metal ion in the centre of each four-base unit. Other structures can also be formed, with the central set of four bases coming from either a single strand folded around the bases, or several different parallel strands, each contributing one base to the central structure. In addition to these stacked structures, telomeres also form large loop structures called telomere loops, or T-loops. Here, the single-stranded DNA curls around in a long circle stabilized by telomere-binding proteins.
According to Fritz, China has expanded its cyber capabilities and military technology by acquiring foreign military technology. Fritz states that the Chinese government uses "new space-based surveillance and intelligence gathering systems, Anti-satellite weapon, anti-radar, infrared decoys, and false target generators" to assist in this quest, and that they support their "Informatisation" of their military through "increased education of soldiers in cyber warfare; improving the information network for military training, and has built more virtual laboratories, digital libraries and digital campuses." Through this informatisation, they hope to prepare their forces to engage in a different kind of warfare, against technically capable adversaries. Foreign Policy magazine put the size of China's "hacker army" at anywhere from 50,000 to 100,000 individuals. Diplomatic cables highlight US concerns that China is using access to Microsoft source code and 'harvesting the talents of its private sector' to boost its offensive and defensive capabilities. While China continues to be held responsible for a string of cyber-attacks on a number of public and private institutions in the United States, India, Russia, Canada, and France, the Chinese government denies any involvement in cyber-spying campaigns. The administration maintains the position that China is also victim to an increasing number of cyber-attacks. Most reports about China's cyber warfare capabilities have yet to be confirmed by the Chinese government.
Successful bead beating is dependent not only on design features of the shaking machine (which take into consideration shaking oscillations frequency, shaking throw or distance, shaking orientation and vial orientation), but also the selection of correct bead size (0.1–6 mm (0.004–0.2 in) diameter), bead composition (glass, ceramic, steel) and bead load in the vial. In most laboratories, bead beating is done in batch sizes of one to twenty-four sealed, plastic vials or centrifuge tubes. The sample and tiny beads are agitated at about 2000 oscillations per minute in specially designed reciprocating shakers driven by high power electric motors. Cell disruption is complete in 1–3 minutes of shaking. Significantly faster rates of cell disruption are achieved with a bead beater variation called SoniBeast. Differing from conventional machines, it agitates the beads using a vortex motion at 20,000 oscillations per minute. Larger bead beater machines that hold deep-well microtiter plates also shorten process times, as do Bead Dispensers designed to quickly load beads into multiple vials or microplates. Pre-loaded vials and microplates are also available. All high energy bead beating machines warm the sample about 10 degrees per minute. This is due to frictional collisions of the beads during homogenization. Cooling of the sample during or after bead beating may be necessary to prevent damage to heat-sensitive proteins such as enzymes.
Hirsutism is excessive body hair on parts of the body where hair is normally absent or minimal. The word is from the early 17th century: from Latin hirsutus meaning "hairy". It usually refers to a male pattern of hair growth in a female that may be a sign of a more serious medical condition, especially if it develops well after puberty. Cultural stigma against hirsutism can cause much psychological distress and social difficulty. Discrimination based on facial hirsutism often leads to the avoidance of social situations and to symptoms of anxiety and depression. Hirsutism is usually the result of an underlying endocrine imbalance, which may be adrenal, ovarian, or central. It can be caused by increased levels of androgen hormones. The amount and location of the hair is measured by a Ferriman–Gallwey score. It is different from hypertrichosis, which is excessive hair growth anywhere on the body. Treatments may include certain birth control pills, antiandrogens, or insulin sensitizers. Hirsutism affects between 5 and 15% of women across all ethnic backgrounds. Depending on the definition and the underlying data, approximately 40% of women have some degree of facial hair. About 10 to 15% of cases of hirsutism are idiopathic with no known cause.
Sources: en.wikipedia.org
=== EC 1.14.14 With reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen === EC 1.14.14.1: unspecific monooxygenase EC 1.14.14.2: Now included with EC 1.14.14.1 unspecific monooxygenase EC 1.14.14.3: alkanal monooxygenase (FMN-linked) EC 1.14.14.4: identical to EC 1.14.15.7, choline monooxygenase.
== Internal standard yield == Yields can also be calculated by measuring the amount of product formed (typically in the crude, unpurified reaction mixture) relative to a known amount of an added internal standard, using techniques like Gas chromatography (GC), High-performance liquid chromatography, or Nuclear magnetic resonance spectroscopy (NMR spectroscopy) or magnetic resonance spectroscopy (MRS). A yield determined using this approach is known as an internal standard yield. Yields are typically obtained in this manner to accurately determine the quantity of product produced by a reaction, irrespective of potential isolation problems. Additionally, they can be useful when isolation of the product is challenging or tedious, or when the rapid determination of an approximate yield is desired. Unless otherwise indicated, yields reported in the synthetic organic and inorganic chemistry literature refer to isolated yields, which better reflect the amount of pure product one is likely to obtain under the reported conditions, upon repeating the experimental procedure.
=== Lozano-Fernandez et al. (2019) === In 2019, similar to previous studies, such as Oakley et al. (2013) and Schwentner et al. (2017), Lozano-Fernandez et al. divided Pancrustacea into Allotriocarida, along with Oligostraca and Multicrustacea, as the three main divisions of subphylum Pancrustacea, embracing the traditional crustaceans and the hexapods (including insects). Lozano-Fernandez et al. also proposed a new group Athalassocarida for the Labiocarida plus Branchiopoda clade (derived from "Athalasso" [Greek: nonmarine] and "carida" [Greek: prawn]), thereby referring to a grouping of pancrustaceans where all extant members either live in nonmarine settings or reverted to a marine life-style secondarily.
== Development == The mod was made by Cayle George, an ex-Valve employee who previously worked on Team Fortress 2 and Portal 2. On August 17, Future Games Select released a trailer of the mod, with George announcing the release of the mod on the forum The Whole Half Life on September 1. The music was made by Garrett "Lazerhawk" Hays, a synthwave producer.
=== Kidney disease === Patients with chronic kidney disease and end-stage renal disease are at higher risk for infections, and procalcitonin has been studied in these populations, who often have higher levels. Procalcitonin can be dialyzed, and so levels are dependent upon when patients receive hemodialysis. While there is no formally accepted cutoff value for patients undergoing HD, using a value of greater or equal to 0.5 ng/mL yielded a sensitivity of 97-98% and a specificity of 70-96%.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.